UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2001
US ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-26190 84-1213501
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification Number)
16825 Northchase Drive
Suite 1300
Houston, Texas 77060
(Address of principal executive offices) (Zip Code)
(832) 601-8766
(Registrant's telephone number, including area code)
ITEM 5. Other Events
ITEM 9. Regulation FD Disclosure
On September 30, 2001, US Oncology, Inc. issued a press release
describing certain steps that the company is taking with respect to a
repositioning of its business model. That press release is attached hereto as
an exhibit and incorporated herein in its entirety. The company is hosting a
conference call to discuss its announcement further, and details concerning that
conference call are set forth in a press release issued on September 28, 2001.
That press release is also attached hereto as an exhibit and incorporated herein
in its entirety.
In addition, the company will be making a presentation at an investor
conference on October 2, 2001. Details concerning that conference are set forth
in a press release issued on September 27, 2001. That press release is attached
hereto as an exhibit and incorporated herein in its entirety. The content of the
slide show to be utilized in connection with that presentation is attached
hereto as an exhibit and incorporated herein in its entirety.
In connection with the "safe harbor" provisions for forward-looking
statements that are contained in the U.S. federal securities laws, the company
is also filing as an exhibit hereto a set of cautionary statements identifying
important factors that could cause US Oncology's actual results to differ
materially from those contained in forward-looking statements made in writing or
in oral statements by the company or on its behalf. Also known as "risk
factors," this set of statements should be considered in addition to the risk
factors and cautionary statements previously filed by the company, most recently
in its Annual Report on Form 10-K for the fiscal year ended December 31, 2000.
The additional risk factors are attached hereto as an exhibit and incorporated
herein in their entirety.
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit 1 Press release dated September 30, 2001
Exhibit 2 Press release dated September 28, 2001
Exhibit 3 Press release dated September 27, 2001
Exhibit 4 Investor Presentation
Exhibit 5 Forward-Looking Statements and Risk Factors
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
US ONCOLOGY, INC.
Date: September 30, 2001 By: /s/ R. Dale Ross
-----------------------------------
Name: R. Dale Ross
Title: Chairman of the Board and
Chief Executive Officer